Baseline patient demographic, clinical and management characteristics associated with three year total mortality in 28 day survivors
| Sex differences | Three year survival differences | ||||||
|---|---|---|---|---|---|---|---|
| Men (n=1519) | Women (n=271) | p | Deceased (n=215) | Survivors (n=1575) | p | ||
| Age:mean (SD) | 58.9 (10.1) | 64.0 (8.1) | <0.001 | 65.4 (7.7) | 59.7 (10.1) | <0.001 | |
| Sex (% women) | — | — | — | 27.4 | 13.5 | <0.001 | |
| Hypertension (%) | 39.0 | 59.1 | <0.001 | 50.5 | 41.1 | 0.01 | |
| Diabetes (%) | 16.7 | 48.0 | <0.001 | 30.2 | 20.4 | 0.001 | |
| Current smokers (%) | 68.9 | 7.8 | <0.001 | 46.2 | 61.6 | <0.001 | |
| Angina (%) | 46.7 | 51.7 | 0.15 | 52.4 | 46.8 | 0.15 | |
| History of cardiac failure (%)3-151 | 7.1 | 14.9 | 0.008 | 18.4 | 7.2 | 0.002 | |
| Clinical characteristics of acute event and interventions | |||||||
| Anterior myocardial infarction (%) | 44.1 | 53.5 | 0.005 | 48.1 | 45.2 | 0.48 | |
| APE/cardiogenic shock (%) | 5.4 | 15.8 | <0.001 | 19.2 | 5.3 | <0.001 | |
| Severe arrhythmia (%)3-150 | 10.8 | 9.8 | 0.7 | 15.0 | 10.0 | 0.03 | |
| Thrombolysis (%)3-152 | 37.2 | 14.9 | <0.001 | 17.7 | 35.4 | 0.002 | |
| Antiplatelet drugs (%)3-152 | 81.6 | 85.1 | 0.43 | 75.9 | 82.8 | 0.17 | |
| 28 day coronary angiograms (%) | 4.1 | 5.5 | 0.4 | 3.8 | 4.5 | 0.78 | |
| 28 day revascularisation (%)3-153 | 1.1 | 1.8 | 0.5 | 1.0 | 1.3 | 1 | |
| Events during three year follow up (after day 28) | |||||||
| Three year mortality (%) | 21.8 | 10.3 | <0.001 | — | — | — | |
| Three year coronary angiograms (%) | 13.6 | 12.8 | 0.8 | 9.2 | 14.0 | 0.09 | |
| Three year revascularisation (%)3-153 | 7.0 | 7.9 | 0.74 | 5.5 | 7.4 | 0.42 | |
| Three year non-fatal Q wave reinfarction (%) | 5.1 | 4.2 | 0.63 | 6.1 | 4.8 | 0.50 | |
APE = acute pulmonary oedema during acute phase.
↵3-150 Ventricular fibrillation or tachycardia requiring immediate medical intervention during acute phase.
↵3-151 Only after 1988.
↵3-152 In patients admitted after introduction of routine antiplatelet drugs and thrombolysis (1988).
↵3-153 Percutaneous transluminal coronary angioplasty or coronary bypass surgery.